Heartseed Inc.

2023

20231129

Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at Global Cardiovascular Clinical Trials Forum during Nov 30-Dec 2

20231110

Seminar Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at Fierce Biotech Webinar on Nov. 28.

PR Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

PR Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

PR Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

PR Heartseed Announces Positive 26-week Data for the First Patient in the Phase 1/2 Clinical Trial (LAPiS Study) Dosed With HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure

Media Heartseed selected as "Six companies that have made their name in the cardiovascular space" by LABIOTECH

PR Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure

Media News article about the initiation of a clinical trial of Heartseed was published in Nature Medicine.

PR Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.

1 2